Ageless Forever offers individualized weight loss programs under the direction and supervision of Dr. John Pierce and his diet / nutrition specialized medical staff.
Successful weight loss is achievement of weight loss that is then kept off forever. Thus, it encompasses two phases; the weight loss phase and the maintenance phase.
At Ageless Forever we emphasize both weight loss and weight loss maintenance, and use specific strategies targeted to every individual's weight loss status and phase
Weight Loss Phase
Depending on how much weight you want/need to lose, and your risk factors, we offer different diet approaches.
* HCG diet for rapid weight loss
* Phentermine plus 5-HTP/Carbidopa
* Weight loss by changing eating habits
Regardless of what diet program you prefer, we will tailor the diet to your unique health status, personal food preferences, goals and/or medical needs.
In contrast to most other weight loss programs, Dr Pierce tailors the diet for every unique patient. His mantra is "there is no one-size-fits-all" especially when it comes to dieting and long-lasting weight loss.
While the different approaches that are offered at Ageless Forever can be categorized into three groups, most of the time a combination of approaches is needed for best results. Dr Pierce excels in developing tailored weight loss programs to his patients' unique needs and goals, for maximal effect and patient satisfaction.
Below is a description of the weight loss approaches that we offer at Ageless Forever.
Our “Rapid Loss Weight Loss Protocol” is based on the "HCG diet". It is for people who need to drop weight quickly. This is a very intensive and restrictive weight loss program that is best suited for obese people who need to lose a large amount of weight for medical reasons.
The HCG diet works in some people by reducing hunger and improving adherence to calorie restricted diets.[1-3] However, it is very restrictive and not for everybody.
Phentermine plus 5-HTP/Carbidopa
Mechanism of action:
- Phentermine increases norepinephrine release, and thus acts as a sympathomimetic agent. Sympathomimetic medications, like phentermine, decrease food intake, increase resting metabolic rate (RMR), and thermogenic responses to food intake and cold exposure.
- The combination of 5-HTP/Carbidopa enhances the transport of 5-HTP via the blood-brain barrier, which makes more 5-HTP available to the brain and central nervous system (CNS) where it is converted to serotonin. It also reduced nausea.
Phentermine is the most commonly prescribed anti-obesity medication in the United States, and has been so for several decades. Phentermine is pharmacologically related to amphetamine, which acts centrally in the brain as an appetite suppressant. Appetite suppressant medications act primarily on the neurotransmitters of the central nervous system to reduce food intake. Appetite suppressants are useful adjuncts to diet programs, and might help selected patients to achieve and maintain weight loss.
Serotonin is a neurotransmitter that regulates food intake, satiety and mood, as well as sleep onset, blood pressure, and pain sensitivity.[7, 8] Serotonin-releasing brain neurons are unique in that the amount of serotonin they release is controlled by food intake: carbohydrate consumption - acting via insulin secretion and the "plasma tryptophan ratio" - increases serotonin release.
High levels of serotonin in the brain gives rise to the "feel good" sensation, while low serotonin levels can contribute to depression and/or cause craving for carbohydrates.[8, 9] By eating carbohydrates, especially sugars, some people get a euphoric feeling which mimics that of serotonin. Overeating carbohydrates is a frequent cause of weight gain and obesity, which itself can cause depression , thereby creating a vicious circle. Overeating carbohydrates is common among people who become fat when exposed to stress, or in women with premenstrual syndrome, or in patients with "winter depression," or in people who are attempting to give up smoking.
5-HTP (5-Hydroxytryptophan) is the precursor of serotonin  and in high doses (900 mg/d) induces weight loss, although with a high rate of side effects (mainly nausea, due to conversion to serotonin).
Carbidopa inhibits the peripheral conversion of 5-HTP to serotonin, which attenuates the side effects of 5-HTP and allows 5-HTP to reach the CNS where it is converted to serotonin .
Benefits of Combined Medication Therapy for Weight Loss
Notable advantages of combined medication therapy are as follow :
(1) Increased efficacy of treatment through synergic or additive action;
(2) Promotion of endogenous (internally caused by the body) synergism;
(3) Medications that act on different pathways and have different pharmacodynamic actions may beat the compensatory mechanisms involved in homeostasis and thus prevent or delay the formation of the plateau during the effort to lose weight.
(4) Combination of low doses could reduce the risk of adverse effects and increase the tolerability of the treatment.
The regulation of body fat mass and appetite is complex and multi-factorial. Not surprisingly, experience has shown that a medication that targets only one mechanism produces a modest weight loss of 5%–10%. Although weight loss of this magnitude may produce significant reductions in risk factors associated with cardiovascular morbidity and mortality, patients expect cosmetically meaningful reductions in weight (20%–25%). Combining two or more medications that work via different mechanisms, that is ‘‘combination pharmacotherapy’’ is an approach to obtaining cosmetically relevant reductions in weight.
A relatively novel combination pharmacotherapy that has been developed in clinical practice is the combination of phentermine with the serotonin precursor 5-HTP plus the peripheral carbidopa (decarboxylase inhibitor). The combination of phentermine with 5-HTP/Carbidopa is popular among obesity specialists for use in clinical practice, more so than the use of sibutramine or orlistat.
In a study on patients with a mean initial weight of 214 lb (range 147 - 357lb), patients lost on average 5.2 lb in the first week and 10.1 lb after 4 weeks. Expressed as a percentage of initial body weight, patients lost 4.7 % of their initial weight in the first 4 weeks. In the whole patient group, weight loss in the first 4 weeks ranged from 2 to 23 lb. The pounds lost in the first 4 weeks (but not the percentage of initial body weight lost), significantly correlated with the initial weight.
These results show that combination pharmacotherapy can make important contributions to the treatment of overweight and obesity. At Ageless Forever, Dr. Pirece has had great success using this combination with his patients.
Weight loss by changing eating habits
Our less restrictive weight loss diet builds upon the principles of healthy eating. Based on your blood test results and food preferences, we design a diet for you that will be especially effective for your metabolism and risk factors.
You will get personalized caloric requirement calculations, macro-nutrient split calculations, and insight how your food choices affect your metabolism, at loss and risk factors.
Note that we will also take your personal food preferences into account; if you don't like certain foods we will give you healthy alternatives. Thereby we help you develop a healthy eating habits that you are comfortable with and can stick to, and enjoy, for a lifetime.
Call Ageless Forever 702-898-1994 to schedule your weight loss consultation appointment.
Weight Maintenance Phase
During the course of the weight loss phase, we teach you lifestyle strategies and mental tactics to help you adhere to the programs. In this way, by the time you have reached your goal weight, you already have developed the mental skills and nutritional knowledge that will make it possible for you to keep the weight off.
For more information on our personalized weight loss programs, just call us 702-838-1994 or submit the contact form.
- Asher, W.L. and H.W. Harper, Effect of human chorionic gonadotrophin on weight loss, hunger, and feeling of well-being. Am J Clin Nutr, 1973. 26(2): p. 211-8.
- Gusman, H.A., Chorionic gonadotropin in obesity. Further clinical observations. Am J Clin Nutr, 1969. 22(6): p. 686-95.
- Lebon, P., Treatment of overweight patients with chorionic gonadotropin. J Am Geriatr Soc, 1961. 9: p. 998-1002.
- Tentolouris, N., S. Liatis, and N. Katsilambros, Sympathetic system activity in obesity and metabolic syndrome. Ann N Y Acad Sci, 2006. 1083: p. 129-52.
- Cosentino, G., A.O. Conrad, and G.I. Uwaifo, Phentermine and topiramate for the management of obesity: a review. Drug Des Devel Ther, 2013. 7: p. 267-78.
- Bray, G.A., Drug Insight: appetite suppressants. Nat Clin Pract Gastroenterol Hepatol, 2005. 2(2): p. 89-95.
- Wurtman, R.J., F. Hefti, and E. Melamed, Precursor control of neurotransmitter synthesis. Pharmacol Rev, 1980. 32(4): p. 315-35.
- Wurtman, R.J. and J.J. Wurtman, Brain serotonin, carbohydrate-craving, obesity and depression. Obes Res, 1995. 3 Suppl 4: p. 477S-480S.
- Turner, E.H., J.M. Loftis, and A.D. Blackwell, Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther, 2006. 109(3): p. 325-38.
- Hryhorczuk, C., S. Sharma, and S.E. Fulton, Metabolic disturbances connecting obesity and depression. Front Neurosci, 2013. 7: p. 177.
- Shabbir, F., et al., Effect of diet on serotonergic neurotransmission in depression. Neurochem Int, 2013. 62(3): p. 324-9.
- Rothman, R.B., Treatment of obesity with "combination" pharmacotherapy. Am J Ther, 2010. 17(6): p. 596-603.
- Gadde, K.M. and D.B. Allison, Combination pharmaceutical therapies for obesity. Expert Opin Pharmacother, 2009. 10(6): p. 921-5.
- Hendricks, E.J., R.B. Rothman, and F.L. Greenway, How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring), 2009. 17(9): p. 1730-5.